Harnessing the power of CNS dynamics


We design and develop innovative implantable devices based on intrathecal catheters covering a wide number of neurological and neurosurgical indications.

Medtech pipeline

The core of our solutions are implantable devices acting on the CSF . We are in the CSF management and in the controlled delivery of drugs medtech sectors.

Based on our expertise in selective nanoporous membranes and CSF fluidics we have been developing 4 devices acting on the CSF directly:

      • Inverlease: for the treatment of neurodegenerative diseases.
      • Chronorelease: for the sustained delivery of advance therapies.
      • Versatile Liquopheresis: CSF filtration for the treatment of acute pathologies.
      • Smart lumbar drainage: advanced lumbar CSF drainage for the treatment of subarachnoid hemorrhage


One of the major limitations for the development of  treatments for the vast majority of CNS disorders, is to be able to penetrate the selective nature of the blood-brain barrier (BBB). The BBB is highly sealed and selective and hence avoids the entrance of unwanted compounds into the brain when administered by conventional routes (oral, subcutaneous, intravenous). Finding a way to overcome it is key.

We have taken up the challenge of brain drug delivery and we are developing new strategies to make drugs available where they are needed (targeted delivery).


Our solutions rely on proprietary nano-enabled drug delivery systems based on  implantable devices able to deliver drugs to the CNS continuously. After minimally-invasive surgery to get the device implanted, percutaneous access allows easy dosing for long term delivery of drugs with superior effectiveness and safety to conventional routes of administration.


This radical new product is grounded on the novel concept of pseudodelivery, which consists of allowing therapy to work correctly without releasing it into the body. Particularly advanced drugs such as enzymes, antibodies or aptamers work by very specifically binding to their target molecules.

Inverlease can transform how the treatments for neurodegenerative diseases are developed and applied. No other method or device can compare to it, thanks to its distinctive features:

MORE EFFECTIVE– it allows pharma compounds acting where they are needed.

SAFE TO USE– it is the only delivery technology enabling action within the CNS while avoiding the release of drugs, thus avoiding drug-induced immune reactions.

CONVENIENT– Percutaneous redosing

We have shown proof of concept in an animal model of Alzheimer’s disease using a miniaturized prototype for rodents. We have now finished the design and manufacturing of the device for humans which is being tested in larger animals.